REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).
REVLIMID is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).
REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
What you need to know about the REVLIMID REMS® program
Your doctor will enroll you in the REVLIMID REMS® program (formerly known as the RevAssist® program) so that you can receive your medication. Use the materials below to learn more about the REVLIMID REMS® program, and what you need to do.
You can take your mandatory confidential patient survey at CelgeneRiskManagement.com by clicking the button below or by using the Celgene REMS mobile app.
For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
© 2017 year of origin. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.